Press Release Details

View All Press Releases

STAAR Surgical ICL Sales Up 46%; Company Raises Outlook for Full Year 2018

10.31.2018

MONROVIA, Calif.--(BUSINESS WIRE)--Oct. 31, 2018-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the third quarter ended September 28, 2018.

Third Quarter 2018 Overview

  • Net Sales of $31.8 Million Up 35% from the Prior Year Quarter
  • ICL Sales Up 46% and Units Up 56% from the Prior Year Quarter
  • Gross Margin at 75.1% of Sales from 71.8% of Sales in the Prior Year Quarter
  • Earnings per Share of $0.03 versus Earnings per Share of $0.03 in the Prior Year Quarter
  • Non-GAAP Earnings per Share of $0.07 versus Earnings per Share of $0.04 in the Prior Year Quarter
  • Cash, Cash Equivalents and Restricted Cash of $102.3 Million at Quarter End
  • The STAAR Visian® Toric ICL for Myopia received FDA Approval on September 13, 2018.

"STAAR’s operating momentum continued during the third quarter resulting in an increase in sales of 35% over the prior year driven by the growth of our EVO Visian ICL™ family of lenses,” said Caren Mason, President and CEO. “ICL unit growth highlights for the quarter included China up 100%, Japan up 95%, India up 27% and Germany up 20%. We continue to see strengthening in our key international markets as we prepare for Europe’s and Korea’s high implant season beginning this quarter and extending into Q1 2019 with strong trends continuing in our Asian markets as well. In addition, we believe our full year fiscal 2018 sales growth should exceed 30% over 2017, based on current market conditions, and we fully expect to maintain GAAP profitability for the year.”

“We are also pleased to report that implants have begun and the staged rollout of our Toric ICL lens in the U.S. with certified surgeons is in progress and ahead of schedule. Based upon the enthusiastic reception from prominent surgeons to the Toric ICL, we anticipate that this product introduction represents a positive re-entry point for STAAR in the U.S., the world’s second largest market for refractive vision correction procedures. Finally, outside the U.S. our multi-site EVO with Aspheric (EDOF) Optic clinical trial for presbyopia is ongoing. Our Principal Investigator from the initial first-in-person clinical trial of the EVO with Aspheric (EDOF) Optic lens for presbyopia presented his study data during our invitation only Experts Summit for surgeons held immediately ahead of the European Society of Cataract and Refractive Surgeons (ESCRS) meeting in Vienna last month. We are very pleased with the enthusiastic reception his presentation received,” concluded Ms. Mason.

Financial Overview – Q3 2018

Net sales were $31.8 million for the third quarter of 2018, up 35% compared to $23.5 million reported in the prior year quarter. The sales increase was driven by ICL revenue growth of 46% and ICL unit growth of 56% reflecting the increasing contribution from lower diopter lenses and contracted pricing terms based on customer volume achievements.

Gross profit margin for the third quarter of 2018, was 75.1% compared to the prior year period of 71.8%. The 330 basis point improvement in gross margin resulted from lower unit costs, favorable product and country mix, and lower freight and inventory provisions, partially offset by the effect of lower average selling prices.

Operating expenses for the third quarter of 2018 were $22.3 million compared to the prior year quarter of $15.8 million and flat sequentially. General and administrative expenses were $6.1 million compared to the prior year quarter of $4.7 million. The increase in general and administrative expenses was due to an increase in compensation costs including stock-based compensation, facilities costs, travel, and investments in enhanced cybersecurity systems. Marketing and selling expenses were $10.6 million compared to the prior year quarter of $6.5 million and flat sequentially. The increase in marketing and selling expenses was due to a calendar shift in ESCRS from the prior year’s fourth quarter and increased investments in digital, consumer, and strategic marketing and commercial infrastructure. Research and development expenses were $5.6 million compared to the prior year quarter of $4.6 million. The increase in research and development expenses was due to an increase in clinical trial expenses, medical affairs, and regulatory expenses.

Net income for the third quarter of 2018 was approximately $1.5 million or $0.03 per share compared with net income of $1.2 million or $0.03 per share for the prior year quarter. Adjusted Net Income for the third quarter of 2018 was $3.4 million or $0.07 per share, compared to Adjusted Net Income in the prior year quarter of $1.5 million or $0.04 per share. The reconciliation between GAAP and non-GAAP financial information is provided in the financial tables included with this release.

Cash, cash equivalents and restricted cash at September 28, 2018 totaled $102.3 million, compared to $18.6 million at the end of the fourth quarter of 2017, and $21.4 million at the end of the second quarter of 2018. The sequential increase in cash, cash equivalents and restricted cash includes $8.1 million in cash generated from operations and approximately $72.2 million in net cash from financing activities reflecting primarily the proceeds from the sale of common stock, which closed August 10, 2018.

Conference Call

The Company will host a conference call and webcast today, Wednesday, October 31, 2018 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 7281609), please dial 855-765-5684 for domestic participants and 262-912-6252 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Conference ID 7281609) will be available beginning approximately one hour after the call’s conclusion for seven days. This replay can be accessed by dialing 855-859-2056 for domestic callers and 404-537-3406 for international callers. An archived webcast will also be available at www.staar.com.

Use of Non-GAAP Financial Measures

This press release includes supplemental non-GAAP financial information, which STAAR believes investors will find helpful in understanding its operating performance. “Adjusted Net Income (Loss)” and “Adjusted Net Income (Loss) Per Share” exclude the following items that are included in “Net Income (Loss)” as calculated in accordance with U.S. generally accepted accounting principles (“GAAP”): gain or loss on foreign currency transactions, stock-based compensation expenses, and quality remediation expenses in 2017. Management believes that “Adjusted Net Income (Loss),” “Adjusted Net Income (Loss) Per Share” are useful to investors in gauging the outcome of the key drivers of the business performance: the ability to increase sales revenue and our ability to increase profit margin by improving the mix of high value products while reducing the costs over which management has control. Management has excluded quality remediation expenses in 2017 because their inclusion may mask underlying trends in our business performance.

Management has also excluded gains and losses on foreign currency transactions because of the significant fluctuations that can result from period to period as a result of market driven factors. Stock-based compensation expenses consist of expenses for stock options and restricted stock under the Financial Accounting Standards Board’s Accounting Standards Codification (ASC) 718. In calculating Adjusted Net Income (Loss) and Adjusted Net Income (Loss) Per Share, STAAR excludes these expenses because they are non-cash expenses and because of the complexity and considerable judgment involved in calculating their values. In addition, these expenses tend to be driven by fluctuations in the price of our stock and not by the same factors that generally affect our other business expenses.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or "ICL", which includes the EVO Visian ICL™ product line. More than 900,000 Visian ICLs have been implanted to date. To learn more about the ICL go to: www.discovericl.com. STAAR has approximately 400 full-time equivalent employees and markets lenses in over 75 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo, CA and Monrovia, CA. For more information, please visit the Company's website at www.staar.com.

Safe Harbor

All statements in this press release that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, including those relating to the plans, strategies, and objectives of management for future operations or prospects for achieving such plans, expectations for sales, revenue, earnings, marketing and clinical initiatives, regulatory approvals, quality, operations and other expense, or expense timing, success and timing of new or improved products, clinical trials, research and development activities, investment imperatives, and any statements of assumptions underlying any of the foregoing. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the Company’s Annual Report on Form 10-K for the year ended December 29, 2017 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events.

These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; changes in currency exchange rates; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before approval (including but not limited to FDA requirements regarding the EVO Visian ICL family of lenses and international regulatory requirements to obtain a presbyopia correction claim for the EVO Visian ICL with EDOF), or to take enforcement action; research and development efforts; potential international trade disputes; the purchasing patterns of our distributors carrying inventory in the market; and the willingness of surgeons and patients to adopt a new or improved product and procedure. The Visian ICL with CentraFLOW, now known as EVO Visian ICL, is not approved for sale in the United States.

Consolidated Balance Sheets    
(in 000's)
Unaudited
 

September 28,

December 29,

ASSETS

2018

2017

Current assets:
Cash and cash equivalents $ 102,195 $ 18,520
Accounts receivable trade, net 23,732 20,035
Inventories, net 16,180 13,674
Prepayments, deposits, and other current assets   5,190     4,207  
Total current assets   147,297     56,436  
Property, plant, and equipment, net 11,462 9,776
Intangible assets, net 244 271
Goodwill 1,786 1,786
Deferred income taxes 1,201 1,242
Other assets   998     967  
Total assets $ 162,988   $ 70,478  
 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Line of credit $ 4,162 $ 4,438
Accounts payable 8,282 6,033
Obligations under capital leases 1,359 1,278
Allowance for sales returns 2,802 2,546
Other current liabilities   10,935     7,339  
Total current liabilities   27,540     21,634  
Obligations under capital leases 662 531
Deferred income taxes 679 350
Asset retirement obligations 201 202
Deferred rent 203 172
Pension liability   4,839     4,653  
Total liabilities   34,124     27,542  
 
 
 
Stockholders' equity:
Common stock 441 414
Additional paid-in capital 287,000 204,920
Accumulated other comprehensive loss (1,201 ) (1,150 )
Accumulated deficit   (157,376 )   (161,248 )
Total stockholders' equity   128,864     42,936  
Total liabilities and stockholders' equity $ 162,988   $ 70,478  
 
Consolidated Statements of Operations              
(In 000's except for per share data)
Unaudited
 
 
Three Months Ended Nine-Months Ended
% of

September 28,

% of

September 29,

Fav (Unfav) % of

September 28,

% of

September 29,

Fav (Unfav)
Sales

2018

Sales

2017

Amount %   Sales

2018

Sales

2017

Amount %  
Net sales 100.0 % $ 31,770 100.0 % $ 23,473 $ 8,297 35.3 % 100.0 % $ 92,768 100.0 % $ 65,759 $ 27,009 41.1 %
 
Cost of sales 24.9 %   7,910   28.2 %   6,624     (1,286 ) -19.4 % 26.1 %   24,250   28.7 %   18,859     (5,391 ) -28.6 %
 
Gross profit 75.1 %   23,860   71.8 %   16,849     7,011   41.6 % 73.9 %   68,518   71.3 %   46,900     21,618   46.1 %
 
Selling, general and administrative expenses:
General and administrative 19.2 % 6,087 20.1 % 4,716 (1,371 ) -29.1 % 19.5 % 18,054 21.9 % 14,380 (3,674 ) -25.5 %
Marketing and selling 33.4 % 10,620 27.7 % 6,495 (4,125 ) -63.5 % 31.0 % 28,733 31.1 % 20,473 (8,260 ) -40.3 %
Research and development 17.5 %   5,570   19.6 %   4,594     (976 ) -21.2 % 17.6 %   16,323   21.9 %   14,418     (1,905 ) -13.2 %
Total selling, general, and administrative expenses 70.1 % 22,277 67.4 % 15,805 (6,472 ) -40.9 % 68.1 % 63,110 74.9 % 49,271 (13,839 ) -28.1 %
 
Operating income (loss) 5.0 %   1,583   4.4 %   1,044     539   51.6 % 5.8 %   5,408   -3.6 %   (2,371 )   7,779   328.1 %
 
Other income (expense):
Interest expense, net -0.1 % (29 ) -0.1 % (27 ) (2 ) -7.4 % -0.1 % (65 ) -0.1 % (88 ) 23 26.1 %
Gain (loss) on foreign currency transactions 0.2 % 52 1.9 % 444 (392 ) -88.3 % -0.6 % (545 ) 1.2 % 738 (1,283 ) -173.8 %
Royalty income 0.5 % 159 0.6 % 141 18 12.8 % 0.5 % 465 0.6 % 400 65 16.3 %
Other income (expense), net 0.1 %   40   -0.1 %   (19 )   59   310.5 % 0.1 %   61   0.0 %   17     44   258.8 %
Total other income (expense), net 0.7 %   222   2.3 %   539     (317 ) -58.8 % -0.1 %   (84 ) 1.7 %   1,067     (1,151 ) -107.9 %
 
Income (loss) before provision for income taxes 5.7 % 1,805 6.7 % 1,583 222 14.0 % 5.7 % 5,324 -1.9 % (1,304 ) 6,628 508.3 %
 
Provision for income taxes 1.1 %   346   1.7 %   410     64   15.6 % 1.6 %   1,452   1.1 %   697     (755 ) -108.3 %
 
Net income (loss) 4.6 % $ 1,459   5.0 % $ 1,173   $ 286   24.4 % 4.1 % $ 3,872   -3.0 % $ (2,001 ) $ 5,873   293.5 %
 
 
Net income (loss) per share - basic $ 0.03   $ 0.03   $ 0.09   $ (0.05 )
Net income (loss) per share - diluted $ 0.03   $ 0.03   $ 0.09   $ (0.05 )
 
Weighted average shares outstanding - basic   43,054     41,110     42,065     40,939  
Weighted average shares outstanding - diluted   46,025     42,104     44,618     40,939  
 
Consolidated Statements of Cash Flows        
(in 000's)
Unaudited
  Three Months Ended Nine-Months Ended

September 28,
2018

September 29,
2017

September 28,
2018

September 29,
2017

 
Cash flows from operating activities:
Net income (loss) $ 1,459 $ 1,173 $ 3,872 $ (2,001 )
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation of property and equipment 624 796 1,792 2,344
Amortization of long-lived intangibles 9 56 26 166
Deferred income taxes 5 155 363 164
Change in net pension liability 74 65 233 95
Stock-based compensation expense 2,027 807 4,926 2,185
Loss on disposal of property and equipment 2 22 8 22
Provision for sales returns and bad debts 248 120 892 186
Inventory provision 428 478 1,181 1,267
Changes in working capital:
Accounts receivable 2,401 62 (3,989 ) 41
Inventories (2,089 ) (183 ) (3,625 ) 725
Prepayments, deposits and other current assets (132 ) (486 ) (1,021 ) (764 )
Accounts payable 1,165 (984 ) 2,121 (2,751 )
Other current liabilities   1,895     1,023     3,643     62  
Net cash provided by (used in) operating activities   8,116     3,104     10,422     1,741  
 
Cash flows from investing activities:
Acquisition of property and equipment   (452 )   (345 )   (1,721 )   (969 )
Net cash used in investing activities   (452 )   (345 )   (1,721 )   (969 )
 
Cash flows from financing activities:
Repayment on line of credit (251 ) - (251 ) -
Repayment of capital lease obligations (515 ) (323 ) (1,396 ) (984 )
Proceeds from sale-leaseback transactions - - - -
Net proceeds from public offering of common stock 72,150 - 72,150 -
Repurchase of employee common stock for taxes withheld - - - (234 )

Proceeds from vested restricted stock and exercise of stock options

  2,175     313     4,582     2,276  
Net cash provided by (used in) financing activities   73,559     (10 )   75,085     1,058  
 
Effect of exchange rate changes on cash, cash equivalents and restricted cash   (274 )   (54 )   (111 )   305  
 
Increase in cash, cash equivalents and restricted cash 80,949 2,695 83,675 2,135
Cash, cash equivalents and restricted cash, at beginning of the period   21,367     13,558     18,641     14,118  
Cash, cash equivalents and restricted cash, at end of the period $ 102,316   $ 16,253   $ 102,316   $ 16,253  
 
Global Sales                        
(in 000's)
Unaudited
 
 
Three Months Ended Nine-Months Ended

September 28,
2018

September 29,
2017

% Change
Fav (Unfav)

September 28,
2018

September 29,
2017

% Change

Fav (Unfav)

Sales by Region

 

 

North America 6.3 % $ 2,003 9.3 % $ 2,192 -8.6 % 6.9 % $ 6,357 10.3 % $ 6,786 -6.3 %
Europe 17.3 % 5,482 21.6 % 5,073 8.1 % 20.8 % 19,290 25.1 % 16,499 16.9 %
Middle East, Africa, Latin America 4.5 % 1,428 5.8 % 1,364 4.7 % 4.5 % 4,193 5.4 % 3,530 18.8 %
Asia Pacific 71.9 %   22,857 63.3 %   14,844 54.0 % 67.8 %   62,928 59.2 %   38,944 61.6 %
Total Sales 100.0 % $ 31,770 100.0 % $ 23,473 35.3 % 100.0 % $ 92,768 100.0 % $ 65,759 41.1 %
 
 
Core Product Sales
ICLs 83.2 % $ 26,418 77.2 % $ 18,110 45.9 % 80.7 % $ 74,868 75.6 % $ 49,698 50.6 %
Other Product Sales
IOLs 12.0 % 3,824 16.5 % 3,892 -1.7 % 13.0 % 12,068 19.6 % 12,875 -6.3 %
Injector Parts and Other 4.8 %   1,528 6.3 %   1,471 3.9 % 6.3 %   5,832 4.8 %   3,186 83.1 %
Total Other Sales 16.8 %   5,352 22.8 %   5,363 -0.2 % 19.3 %   17,900 24.4 %   16,061 11.5 %
Total Sales 100.0 % $ 31,770 100.0 % $ 23,473 35.3 % 100.0 % $ 92,768 100.0 % $ 65,759 41.1 %
 
Reconciliation of Non-GAAP Financial Measure      
(in 000's)
Unaudited Three Months Ended Nine-Months Ended

September 28,
2018

September 29,
2017

September 28,
2018

September 29,
2017

 
Net income (loss) - (as reported) $ 1,459 $ 1,173 $ 3,872 $ (2,001 )
Less:
Foreign currency impact (52 ) (444 ) 545 (738 )
Stock-based compensation expense 2,027 807 4,926 2,185
Quality remediation expense   -     -     -   210  
Net income (loss) - (adjusted) $ 3,434   $ 1,536   $ 9,343 $ (344 )
 
Net income (loss) per share, basic - (as reported) $ 0.03 $ 0.03 $ 0.09 $ (0.05 )
Foreign currency impact - (0.01 ) 0.01 (0.02 )
Stock-based compensation expense 0.05 0.02 0.12 0.05
Quality remediation expense   -     -     -   0.01  
Net income (loss) per share, basic - (adjusted) $ 0.08   $ 0.04   $ 0.22 $ (0.01 )
 
Net income (loss) per share, diluted - (as reported) $ 0.03 $ 0.03 $ 0.09 $ (0.05 )
Foreign currency impact - (0.01 ) 0.01 (0.02 )
Stock-based compensation expense 0.04 0.02 0.11 0.05
Quality remediation expense   -     -     -   0.01  
Net income (loss) per share, diluted - (adjusted) $ 0.07   $ 0.04   $ 0.21 $ (0.01 )
 
Weighted average shares outstanding - Basic 43,054 41,110 42,065 40,939
Weighted average shares outstanding - Diluted 46,025 42,104 44,618 40,939
 
Note: Net income (loss) per share (adjusted), basic and diluted, may not add due to rounding

Source: STAAR Surgical Company

STAAR Surgical Company
Investors & Media
EVC Group
Brian Moore, 310-579-6199
Doug Sherk, 415-652-9100

Multimedia Files:

View All Press Releases